0000000000527989

AUTHOR

Elio Castagnola

showing 16 related works from this author

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients.

2001

Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P=.0001). In a multivariate model without including antifungal prophylaxis, factors associated with bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, p…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAdolescentFeverOpportunistic infectionBacteremiaNeutropeniaInternal medicineMedicineHumansMycosisLeukopeniabusiness.industryOdds ratioAntibiotic ProphylaxisPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseSurgeryLeukemia Myeloid AcuteInfectious DiseasesAntibiotic Prophylaxis/utilization; Antifungal Agents/therapeutic use; Bacteremia/epidemiology; Fever/complications; Leukemia Myeloid Acute/complications; Neutropenia/complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma/complicationsBacteremiaChemoprophylaxisFemalemedicine.symptombusinessFebrile neutropeniaClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study

2021

Background: Many aspects of SARS-CoV-2 infection in children and adolescents remain unclear and optimal treatment is debated. The objective of our study was to investigate epidemiological, clinical and therapeutic characteristics of pediatric SARS-CoV-2 infection, focusing on risk factors for complicated and critical disease.Methods: The present multicenter Italian study was promoted by the Italian Society of Pediatric Infectious Diseases, involving both pediatric hospitals and general pediatricians/family doctors. All subjects under 18 years of age with documented SARS-CoV-2 infection and referred to the coordinating center were enrolled from March 2020.Results: As of 15 September 2020, 75…

Pediatricsmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MIS-CDisease030204 cardiovascular system & hematologyPediatrics03 medical and health sciences0302 clinical medicinechildren030225 pediatricsEpidemiologymedicinebookOriginal Researchmultisystem inflammatory syndromeMIS-C COVID-19business.industrySARS-CoV-2 infectionDisease progressionlcsh:RJ1-570COVID-19lcsh:PediatricsSettore MED/38Icu admissionCOVID-19; MIS-C; SARS-CoV-2 infection; children; multisystem inflammatory syndromeMulticenter studyPediatrics Perinatology and Child HealthPediatric Infectious Diseasebook.journalbusiness
researchProduct

EARLY EFFICACY OF LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF VISCERAL LEISHMANIASIS

1996

The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory …

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiprotozoal AgentsSeverity of Illness IndexGastroenterologyAmphotericin BAmphotericin BInternal medicineAnimalsHumansMedicineLeishmania infantumChildleishmaniasisDrug CarriersChemotherapybiologybusiness.industryPublic Health Environmental and Occupational HealthInfantAnemiaLeishmaniasisGeneral Medicinebiology.organism_classificationmedicine.diseaseInfectious Diseasesmedicine.anatomical_structureVisceral leishmaniasisItalyChild PreschoolLiposomesImmunologyLeishmaniasis VisceralFemaleParasitologyLiposomal amphotericinHemoglobinBone marrowLeishmania infantumbusinessmedicine.drug
researchProduct

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).

1996

We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infa…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentmedicine.medical_treatmentGastroenterologyDrug Administration ScheduleleishmanisisInternal medicineAmphotericin BAmphotericin BMedicinevisceral leishmaniasisAnimalsHumansLeishmania infantumAdverse effectChildChemotherapyDrug Carriersbiologybusiness.industryInfantLeishmaniasisMiddle Agedmedicine.diseasebiology.organism_classificationSurgeryInfectious DiseasesVisceral leishmaniasisTreatment OutcomeTotal doseChild PreschoolLiposomesLeishmaniasis VisceralLiposomal amphotericinFemaleLeishmania infantumbusinessmedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Additional file 2 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 2 figure. Hierarchy of MedDra clinically-validated international medical terminology.

3. Good health
researchProduct

Additional file 2 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 2 figure. Hierarchy of MedDra clinically-validated international medical terminology.

3. Good health
researchProduct

Additional file 1 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 1 figure. Flowchart of the process.

3. Good health
researchProduct

Additional file 4 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 4 Table 2. Concomitant medications administered at the time of “confirmed OI”. Bio: biologic, mtx: methotrexate; ste: systemic steroids; sDMARDs: synthetic disease modifying antirheumatic drugs; *sDMARDs are intendend other than MTX.

musculoskeletal diseases3. Good health
researchProduct

Additional file 1 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 1 figure. Flowchart of the process.

3. Good health
researchProduct

Additional file 3 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 3 Table 1. Complete table with the frequency of the 682 infections adjudicated by the SAC. Infections were reported after evaluation of the cases available in Pharmachild compared to the pathogens/presentations in the provisional list approved by the Safety Adjudication Committee (SAC). Data are presented as per the MedDRA High Level Term (HLT) and Preferred Term (PT) sorted by frequencies in descending order (HLT and then PT). *For definition see Step 5.

3. Good health
researchProduct

Daptomycin for children in clinical practice experience

2016

Data on daptomycin use in the pediatric setting are scanty. We conducted a multicenter, retrospective study on 46 children treated with intravenous daptomycin at a mean dosage of 7.0 mg/kg/d, for a median of 14 days. Three children had adverse events possibly related to daptomycin. The drug was overall well tolerated, even with prolonged treatment.

Male0301 basic medicinePediatricsmedicine.disease_causePediatrics0302 clinical medicinepolycyclic compounds030212 general & internal medicineChildChildrenMedicine (all)OsteomyelitisBacterial InfectionsPerinatology and Child HealthAnti-Bacterial AgentsClinical PracticeInfectious DiseasesChild PreschoolAdministration IntravenousFemalelipids (amino acids peptides and proteins)Children; Daptomycin; Methicillin-resistant Staphylococcus aureus; Osteomyelitis; Sepsis; Pediatrics Perinatology and Child Health; Medicine (all); Microbiology (medical); Infectious DiseasesMethicillin-resistant Staphylococcus aureusmedicine.drugMicrobiology (medical)medicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse Reactions030106 microbiologyChildren; Daptomycin; Methicillin-resistant Staphylococcus aureus; Osteomyelitis; Sepsis;Sepsis03 medical and health sciencesDaptomycinSepsismedicineHumansAdverse effectRetrospective Studiesbusiness.industryOsteomyelitisInfant NewbornInfantRetrospective cohort studybiochemical phenomena metabolism and nutritionbacterial infections and mycosesmedicine.diseaseMethicillin-resistant Staphylococcus aureuscarbohydrates (lipids)Pediatrics Perinatology and Child HealthDaptomycinbusinessProlonged treatment
researchProduct

Additional file 4 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 4 Table 2. Concomitant medications administered at the time of “confirmed OI”. Bio: biologic, mtx: methotrexate; ste: systemic steroids; sDMARDs: synthetic disease modifying antirheumatic drugs; *sDMARDs are intendend other than MTX.

musculoskeletal diseases3. Good health
researchProduct

Additional file 3 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adj…

2020

Additional file 3 Table 1. Complete table with the frequency of the 682 infections adjudicated by the SAC. Infections were reported after evaluation of the cases available in Pharmachild compared to the pathogens/presentations in the provisional list approved by the Safety Adjudication Committee (SAC). Data are presented as per the MedDRA High Level Term (HLT) and Preferred Term (PT) sorted by frequencies in descending order (HLT and then PT). *For definition see Step 5.

3. Good health
researchProduct

Surgical Antimicrobial Prophylaxis in Abdominal Surgery for Neonates and Paediatrics: A RAND/UCLA Appropriateness Method Consensus Study.

2022

Surgical site infections (SSIs), i.e., surgery-related infections that occur within 30 days after surgery without an implant and within one year if an implant is placed, complicate surgical procedures in up to 10% of cases, but an underestimation of the data is possible since about 50% of SSIs occur after the hospital discharge. Gastrointestinal surgical procedures are among the surgical procedures with the highest risk of SSIs, especially when colon surgery is considered. Data that were collected from children seem to indicate that the risk of SSIs can be higher than in adults. This consensus document describes the use of preoperative antibiotic prophylaxis in neonates and children that ar…

Microbiology (medical)Infectious Diseasespancreas surgerySettore MED/41 - ANESTESIOLOGIAPharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsabdominal surgerygastrointestinal endoscopyBiochemistryMicrobiologyabdominal surgery; appendectomy; gastrointestinal endoscopy; liver surgery; pancreas surgeryappendectomyliver surgery
researchProduct